Progesterone Timing in the Menstrual Cycle
The timing of progesterone administration depends entirely on the clinical indication—it is NOT given based on menstrual cycle day for most indications, but rather based on gestational age for preterm birth prevention or specific cycle days for menstrual disorders.
For Preterm Birth Prevention (Primary Evidence-Based Use)
Women with Prior Spontaneous Preterm Birth
17-hydroxyprogesterone caproate (17P) should be initiated at 16-20 weeks of gestation and continued weekly until 36 weeks 1. This is independent of menstrual cycle timing since the patient is already pregnant. The evidence strongly supports 17P (250 mg IM weekly) over vaginal progesterone for this indication, with demonstrated reductions in preterm birth <37 weeks (RR 0.66), <32 weeks, and neonatal complications including intraventricular hemorrhage 1.
Women with Short Cervical Length (No Prior PTB)
When cervical length screening identifies a short cervix (≤20 mm) at 18-24 weeks gestation, vaginal progesterone (90-mg gel or 200-mg suppository) should be initiated immediately upon detection 1. Again, this is gestational age-dependent, not menstrual cycle-dependent.
Critical Pitfall: The 2017 SMFM guidance revision emphasizes that vaginal progesterone has NOT been adequately proven to prevent recurrent preterm birth in women with prior spontaneous PTB, despite earlier recommendations 2. Multiple large RCTs (O'Brien 2007, OPPTIMUM 2016) showed no significant benefit in this population.
For Non-Pregnancy Indications
Secondary Amenorrhea Treatment
Progesterone 400 mg orally should be given as a single daily dose at bedtime for 10 consecutive days 3. This is administered after confirming adequate estrogen priming (not on a specific menstrual cycle day, since these patients are amenorrheic). In clinical trials, this regimen induced withdrawal bleeding in 73.8-76.8% of women within 7 days of the last dose 3.
Endometrial Protection in Postmenopausal Women on Estrogen
Progesterone 200 mg orally should be given at bedtime for 12 consecutive days per 28-day cycle 3. This sequential regimen reduced endometrial hyperplasia from 64% (estrogen alone) to 6% (combination therapy) over 36 months 3.
Contraceptive Injectable Timing (If Applicable)
For depot medroxyprogesterone acetate (DMPA) contraception, initiation should occur within the first 7 days of the menstrual cycle to reliably prevent ovulation 4. When initiated after cycle day 7, ovulation occurred in some women. The "quick start" method (giving DMPA at any cycle day) resulted in higher pregnancy rates and poor continuation 4.
Key Clinical Algorithm:
- Pregnant with prior PTB → Start 17P at 16-20 weeks gestation
- Pregnant with short cervix found on screening → Start vaginal progesterone immediately
- Amenorrhea → Give progesterone 400 mg × 10 days (not cycle-dependent)
- Postmenopausal on estrogen → Give progesterone days 15-26 of each 28-day cycle
- Contraception initiation → Give within first 7 days of menses
Important Safety Note: Progesterone capsules should be taken at bedtime due to significant drowsiness, dizziness, and rarely blurred vision or difficulty walking 3. The oral formulation contains peanut oil and is contraindicated in peanut allergy 3.